Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics reported that the U.S. Food and Drug Administration has approved its drug Lifyorli (relacorilant), used with nab-paclitaxel, to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior bevacizumab-containing regimens.
The approval is based on the pivotal ROSELLA trial in 381 patients, where Lifyorli plus nab-paclitaxel cut the risk of death by 35 percent (hazard ratio 0.65; p=0.0004) and improved median overall survival to 16.0 months, versus 11.9 months with nab-paclitaxel alone. It also reduced the risk of disease progression by 30 percent (hazard ratio 0.70; p=0.008).
Lifyorli is described as the first FDA-approved selective glucocorticoid receptor antagonist and showed a manageable safety profile, though prescribing information carries warnings for neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions and embryo-fetal toxicity, with common side effects including low blood counts, fatigue, nausea, diarrhea, rash and decreased appetite.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 4,000 shares of Common Stock. The gift was made at no stated price by the James N. Wilson and Pamela D. Wilson Trust, an entity through which he holds shares indirectly. Following this transaction, that trust holds 1,102,532 shares, with additional indirect holdings reported through a family partnership and two 2025 grantor retained annuity trusts.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 11,767 shares of common stock at $21.65 per share and on the same day sold 11,767 shares at a weighted average price of $36.01 per share. The sale prices ranged from $35.97 to $36.24 per share and was carried out under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 2,231 shares of common stock, plus 224 shares and 498 shares underlying unvested restricted stock awards that are scheduled to vest in full on the one-year anniversaries of their December 1, 2025 and March 2, 2026 grant dates, respectively, subject to specified conditions. The option exercised for 11,767 shares was fully exercisable before this transaction.
Corcept Therapeutics director Leonard G. Baker Jr. reported buying a total of 100,000 shares of Common Stock in open-market transactions on March 17, 2026. The purchases were split between 75,782 shares at a weighted average price of $33.0022 and 24,218 shares at a weighted average price of $33.5633, with actual trade prices ranging from $32.43 to $33.68.
Following these purchases, Baker directly holds 1,146,631 Corcept shares. He also has indirect interests in 3,308,303 shares held by a limited partnership and 1,095,262 shares held by a trust, while disclaiming beneficial ownership except to the extent of his pecuniary interests.
Director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, made a bona fide gift of 28,000 shares of Corcept Therapeutics common stock on March 13, 2026, with no cash changing hands. The filing shows that, after this gift, the trust held 1,106,532 shares, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of two 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power over the trust and family partnership holdings but disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
Corcept Therapeutics director David L. Mahoney reported a series of routine equity transactions. He exercised stock options covering 30,000 shares of Common Stock at $5.86 per share, converting a derivative position into directly held shares.
To cover the exercise price through a net, cashless exercise, 5,469 shares were withheld at a value of $32.15 per share, which is a tax/payment mechanism rather than an open-market sale. The remaining 24,531 shares were transferred as a bona fide gift to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust and are now reported as indirectly owned.
After these transactions, Mahoney reports 1,237,145 shares of Common Stock held indirectly through the family trust and an additional 46,147 shares held indirectly through The Black Dog Private Foundation. The filing shows no open-market purchases or sales of Corcept Therapeutics stock.
Corcept Therapeutics’ Chief Development Officer William Guyer exercised 8,233 stock options and sold the resulting shares. On March 4, 2026, he exercised options for 8,233 shares of common stock at an exercise price of $21.65 per share and then sold 8,233 shares in the open market at a weighted average price of $35.9949 per share, with individual sale prices ranging from $35.97 to $36.05. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, Guyer held 2,231 shares of common stock directly, as well as options and restricted stock awards, including 224 and 498 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their respective grant dates, subject to specified conditions.
Corcept Therapeutics officer Joseph Douglas Lyon reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 398 shares in a grant or award and another 398 shares tied to a purchase plan, with the price based on that day’s closing price.
On March 3, 2026, 89 shares were disposed of through share withholding to cover tax obligations related to vesting restricted stock units, rather than an open-market sale. Following these transactions, he directly holds 11,230 shares, including unvested restricted stock awards that generally vest one year after their grant dates if required conditions are met.
Corcept Therapeutics executive Sean Maduck reported equity award activity and related tax withholding. On March 2, 2026, he acquired two grants of common stock totaling 908 shares, including 454 purchase-plan shares priced under a company purchase plan and 454 shares granted at no cost as an award. On March 3, 2026, 110 shares were withheld by Corcept at a price of $35.97 per share to cover tax obligations tied to vesting restricted stock units, leaving 8,977 common shares held directly.
The filing also lists indirect ownership stakes through several entities, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two SNM Grantor Retained Annuity Trusts, and Duckhill Capital, LLC. Maduck disclaims beneficial ownership of Duckhill Capital, LLC shares beyond his pecuniary interest.
Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation activity in the company’s common stock. On March 2, 2026, he acquired 499 shares at $35.97 per share under a purchase plan established pursuant to the 2024 Incentive Award Plan, and received an additional 499-share restricted stock award at no stated cost. These awards include unvested restricted stock that will fully vest on the one-year anniversary of each grant if specified service and ownership conditions are met.
On March 3, 2026, 121 shares were disposed of at $35.97 per share to satisfy tax withholding obligations tied to vesting restricted stock units, meaning the shares were withheld by the company rather than sold in the open market. After these transactions, Robb directly held 79,503 shares and indirectly oversaw 11,571 shares held in a custodial account for a child under the Uniform Transfers to Minors Act.